Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity

Lawrence L. Horstman, Benjamin J. Valle-Riestra, Wenche Jy, Fang Wang, Wei Mao, Yeon Ahn

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Desmopressin (DDAVP), an analog of vasopressin (AVP), has wide clinical application as an anti-hemorrhagic (AH) agent. DDAVP in vivo releases vWF from endothelial cells but is reported to have little action on platelets. However, DDAVP is often used to improve hemostasis in platelet dysfunctions. We examined the effect of DDAVP on platelet microparticle (PMP) formation and procoagulant activity in vitro using platelets from normal volunteers and in vivo in six patients receiving DDAVP therapy. In the former, platelets were incubated with DDAVP (0.5 to 25 nM) and PMP released were stained with FITC-labeled MAb α-GP IIb IIIa for flow cytometry. Procoagulant activity was measured in a clot-based assay using Russel's viper venom (RVV) calibrated with cephalin. A mean increase of 2-3 fold was observed in both PMP and procoagulant activity. Parallel to these observations was a dose-dependent rise in organelle-associated Ca2+. The assays were also performed on six patients prior to and at one hour after infusion of DDAVP, and similar but lesser effects were observed. We conclude that DDAVP acts on platelets in vitro, and that these effects may contribute to the hemostatic action of DDAVP in platelet dysfunctions in vivo.

Original languageEnglish
Pages (from-to)163-174
Number of pages12
JournalThrombosis Research
Volume79
Issue number2
DOIs
StatePublished - Jul 15 1995

Fingerprint

Deamino Arginine Vasopressin
Blood Platelets
Viper Venoms
Phosphatidylethanolamines
Platelet Membrane Glycoprotein IIb
Fluorescein-5-isothiocyanate
Hemostatics
Hemostasis
Vasopressins
Organelles
Healthy Volunteers
Flow Cytometry
Endothelial Cells

Keywords

  • DDAVP/desmopressin
  • hemostasis
  • platelet microparticles

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity. / Horstman, Lawrence L.; Valle-Riestra, Benjamin J.; Jy, Wenche; Wang, Fang; Mao, Wei; Ahn, Yeon.

In: Thrombosis Research, Vol. 79, No. 2, 15.07.1995, p. 163-174.

Research output: Contribution to journalArticle

Horstman, Lawrence L. ; Valle-Riestra, Benjamin J. ; Jy, Wenche ; Wang, Fang ; Mao, Wei ; Ahn, Yeon. / Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity. In: Thrombosis Research. 1995 ; Vol. 79, No. 2. pp. 163-174.
@article{0e9be67054dc44fe998505dee0604335,
title = "Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity",
abstract = "Desmopressin (DDAVP), an analog of vasopressin (AVP), has wide clinical application as an anti-hemorrhagic (AH) agent. DDAVP in vivo releases vWF from endothelial cells but is reported to have little action on platelets. However, DDAVP is often used to improve hemostasis in platelet dysfunctions. We examined the effect of DDAVP on platelet microparticle (PMP) formation and procoagulant activity in vitro using platelets from normal volunteers and in vivo in six patients receiving DDAVP therapy. In the former, platelets were incubated with DDAVP (0.5 to 25 nM) and PMP released were stained with FITC-labeled MAb α-GP IIb IIIa for flow cytometry. Procoagulant activity was measured in a clot-based assay using Russel's viper venom (RVV) calibrated with cephalin. A mean increase of 2-3 fold was observed in both PMP and procoagulant activity. Parallel to these observations was a dose-dependent rise in organelle-associated Ca2+. The assays were also performed on six patients prior to and at one hour after infusion of DDAVP, and similar but lesser effects were observed. We conclude that DDAVP acts on platelets in vitro, and that these effects may contribute to the hemostatic action of DDAVP in platelet dysfunctions in vivo.",
keywords = "DDAVP/desmopressin, hemostasis, platelet microparticles",
author = "Horstman, {Lawrence L.} and Valle-Riestra, {Benjamin J.} and Wenche Jy and Fang Wang and Wei Mao and Yeon Ahn",
year = "1995",
month = "7",
day = "15",
doi = "10.1016/0049-3848(95)00102-W",
language = "English",
volume = "79",
pages = "163--174",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity

AU - Horstman, Lawrence L.

AU - Valle-Riestra, Benjamin J.

AU - Jy, Wenche

AU - Wang, Fang

AU - Mao, Wei

AU - Ahn, Yeon

PY - 1995/7/15

Y1 - 1995/7/15

N2 - Desmopressin (DDAVP), an analog of vasopressin (AVP), has wide clinical application as an anti-hemorrhagic (AH) agent. DDAVP in vivo releases vWF from endothelial cells but is reported to have little action on platelets. However, DDAVP is often used to improve hemostasis in platelet dysfunctions. We examined the effect of DDAVP on platelet microparticle (PMP) formation and procoagulant activity in vitro using platelets from normal volunteers and in vivo in six patients receiving DDAVP therapy. In the former, platelets were incubated with DDAVP (0.5 to 25 nM) and PMP released were stained with FITC-labeled MAb α-GP IIb IIIa for flow cytometry. Procoagulant activity was measured in a clot-based assay using Russel's viper venom (RVV) calibrated with cephalin. A mean increase of 2-3 fold was observed in both PMP and procoagulant activity. Parallel to these observations was a dose-dependent rise in organelle-associated Ca2+. The assays were also performed on six patients prior to and at one hour after infusion of DDAVP, and similar but lesser effects were observed. We conclude that DDAVP acts on platelets in vitro, and that these effects may contribute to the hemostatic action of DDAVP in platelet dysfunctions in vivo.

AB - Desmopressin (DDAVP), an analog of vasopressin (AVP), has wide clinical application as an anti-hemorrhagic (AH) agent. DDAVP in vivo releases vWF from endothelial cells but is reported to have little action on platelets. However, DDAVP is often used to improve hemostasis in platelet dysfunctions. We examined the effect of DDAVP on platelet microparticle (PMP) formation and procoagulant activity in vitro using platelets from normal volunteers and in vivo in six patients receiving DDAVP therapy. In the former, platelets were incubated with DDAVP (0.5 to 25 nM) and PMP released were stained with FITC-labeled MAb α-GP IIb IIIa for flow cytometry. Procoagulant activity was measured in a clot-based assay using Russel's viper venom (RVV) calibrated with cephalin. A mean increase of 2-3 fold was observed in both PMP and procoagulant activity. Parallel to these observations was a dose-dependent rise in organelle-associated Ca2+. The assays were also performed on six patients prior to and at one hour after infusion of DDAVP, and similar but lesser effects were observed. We conclude that DDAVP acts on platelets in vitro, and that these effects may contribute to the hemostatic action of DDAVP in platelet dysfunctions in vivo.

KW - DDAVP/desmopressin

KW - hemostasis

KW - platelet microparticles

UR - http://www.scopus.com/inward/record.url?scp=0028998423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028998423&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(95)00102-W

DO - 10.1016/0049-3848(95)00102-W

M3 - Article

VL - 79

SP - 163

EP - 174

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 2

ER -